Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Clinical Cosmetic and Investigational DermatologyOpen Access

Effect of Methotrexate Discontinuation on Psoriatic Patients with Significant Liver Fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTanat YongpisarnKTKunlawat ThadaniponPRPloysyne Rattanakaemakorn

Discussion

Loading...

Member takes

Overview

Pilot study observes liver fibrosis regression in psoriasis patients after methotrexate withdrawal, suggesting potential benefits.

Key Points

  • Fibrosis regression was observed in 5 patients (33.3%) after a mean MTX-free duration of 3.6 years.
  • MTX treatment duration greater than 4 years was significantly associated with fibrosis regression (OR = 16.00; p = 0.043).
  • A cumulative MTX dose greater than 2 grams showed a non-significant trend toward increased odds of fibrosis regression.
  • Given the small sample size, additional larger studies are needed to validate these findings.

Cite This Study

Yongpisarn et al. (2025) studied this question.

synapsesocial.com/papers/68d44a4731b076d99fa53bcbhttps://doi.org/10.2147/ccid.s547056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Detection of significant liver fibrosis in Chinese psoriasis patients receiving methotrexate: a comparison between transient elastography and liver histology2024
  2. 2Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis2024 · 12 citations
  3. 3AB0590 CORRELATION BETWEEN CUMULATIVE METHOTREXATE DOSE, METABOLIC SYNDROME AND HEPATIC FIBROSIS DETECTED BY FIBROSCAN IN PATIENTS RECEIVING METHOTREXATE IN RHEUMATOID ARTHRITIS IN COMPARISON WITH PSORIATIC ARTHRITIS2024
  4. 4A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?2026
  5. 5P118 Assessment of methotrexate-induced liver toxicity in patients with inflammatory rheumatic diseases: an observational study based on FIB-4 and FibroScan2026